Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0001 USD
Change Today 0.00 / 0.00%
Volume 10.0K
SVFC On Other Exchanges
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

intellicell biosciences inc (SVFC) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/4/14 - $0.0025
52 Week Low
03/13/15 - $0.0001
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

intellicell biosciences inc (SVFC) Related Businessweek News

No Related Businessweek News Found

intellicell biosciences inc (SVFC) Details

IntelliCell BioSciences, Inc. operates as a regenerative medicine company in the United States. It develops and commercializes regenerative medicine using adult autologous stromal vascular fraction cells derived from the blood vessels in adipose tissue. The company’s products are intended to treat various clinical conditions, such as aesthetic conditions, orthopedic and sports injuries, and pain, as well as cardiac, gastrointestinal, periodontal, and autistic disorders. It also focuses on undertaking clinical studies in partnership with universities and hospitals for osteoarthritis, gum regeneration, non-healing diabetic ulcers, multiple sclerosis, cartilage regeneration, tendon repair, facial lines and wrinkles, chronic migraine headache, bone regeneration, and hair regeneration indications. In addition, the company is involved in sourcing, selling, and distributing laboratory equipment and supplies, which are used in tissue processing activities. It also licenses its products in Canada, Australia, New Zealand, and Thailand. The company has a collaboration agreement with Hielscher Ultrasonics to develop closed processing system for cell therapy manufacturing. IntelliCell BioSciences, Inc. is based in New York, New York.

intellicell biosciences inc (SVFC) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2013.

intellicell biosciences inc (SVFC) Key Developments

IntelliCell BioSciences, Inc. announced delayed annual 10-K filing

On 04/01/2015, IntelliCell BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

IntelliCell BioSciences Licenses Indication for Diabetes to Invigorcell

IntelliCell BioSciences, Inc. announced a license agreement for the indication of Diabetes Mellitus. Invigorcell will be filing an IND with the FDA for the indication of Diabetes Mellitus. Invigorcell is a biotech company that will utilize the technologies of IntelliCell BioSciences to develop innovative treatments for the normalization of metabolism in both Type 1 and Type 2 diabetes.

IntelliCell BioSciences Announces Collaboration with Hielscher Ultrasonics to Develop Closed Processing System for Cell Therapy Manufacturing

IntelliCell BioSciences, Inc. announced an agreement for the development of a new closed processing system for its cellular therapy manufacturing with Hielscher Ultrasonics. Under the agreement, Hielscher Ultrasonics will provide system design and engineering development for ultrasonic cavitation manufacturing, and IntelliCell Biosciences will use this system in its commercial application of its stromal vascular fraction cellular product, 'SVFC'. In order to separate the stem cells and other beneficial cell types from the fat tissue, the harvested tissue is treated ultrasonically. The ultrasound cavitation technology can be adjusted exactly to the required intensity to break the tissue so that the cells are released for separation, but mildly enough to prevent the stem cells from damage. To improve the ultrasonic cavitation technique, Hielscher developed for IntelliCell a unique ultrasonic reactor, which allows the sonication in a sterile, contamination-free environment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVFC:US $0.00 USD 0.00

SVFC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.10 USD -0.01
Biorestorative Therapies Inc $9.99 USD -0.01
Caladrius Biosciences Inc $1.74 USD -0.05
Cytori Therapeutics Inc $0.44 USD 0.00
StemCells Inc $0.42 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SVFC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELLICELL BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at